Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesInovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
1.41 USD 0.20 ( 16.05%)
Last update at 2026-11-09T15:24:00Z
VOLUME
7501349
Market Cap
119.94M

Momentum Score

…

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.26
Low
1.41
High
52 Week Price Range
0.56
Low
2.72
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Inovio Pharmaceuticals is a clinical-stage biotechnology company developing DNA-based vaccines and immunotherapies delivered via its proprietary electroporation device, pursuing programs for infectious diseases and cancer. Long-term growth may be driven by successful clinical readouts and approvals, strategic partnerships to scale commercialization, and broader adoption of DNA platforms for rapid vaccine design.

Material risks include its early-stage profile with no marketed product, high cash burn and potential dilution, substantial execution and regulatory risk from clinical trial failures, and strong competition from mRNA and viral-vector platforms.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.22
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
-48.49M
Debt / Equity
0.39
ROE
-409.87%
Net Debt
-34.91M
ROCE
-277.23%
Diluted EPS TTM
-1.01

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -84.95M -107.25M -135.12M -277.65M -303.22M
Minority interest - - - 0.00M 0.00M
Net income -84.95M -107.25M -135.12M -287.66M -305.38M
Selling general administrative 32.68M 36996.34M 47.58M 90.19M 53.75M
Selling and marketing expenses - 36959.34M 3.50M - -
Gross profit 0.07M -2.91M 0.83M 10.26M 1.77M
Reconciled depreciation 2.99M 3.13M 4.68M 5.50M 4.73M
Ebit -84.95M -107.08M -133.89M -267.57M -301.22M
Ebitda -81.96M -103.95M -130.39M -268.55M -293.33M
Depreciation and amortization 2.99M 3.13M 3.50M -0.98M 7.88M
Non operating income net other - - - -1.24M 3.27M
Operating income -86.82M -112.40M -143.94M -267.57M -301.22M
Other operating expenses 86.89M 112.62M 144.77M 277.84M 302.99M
Interest expense 0.00M 0.18M 1.22M 1.25M 1.94M
Tax provision - - - - 0.00M
Interest income 2.42M 4.77M 8.20M 4.78M 3.36M
Net interest income 2.42M 4.59M 6.95M 3.53M 1.43M
Income tax expense - -107146.87M 0.00M 10.01M 2.16M
Total revenue 0.07M 0.22M 0.83M 10.26M 1.77M
Total operating expenses 86.89M 111.09M 144.77M 277.84M 302.99M
Cost of revenue 2.99M 3.13M 3.50M - -
Total other income expense net 1.88M -107141.73M 8.82M -10.08M -2.01M
Net income from continuing ops -84.95M -107.25M -164.58M -277.65M -303.22M
Net income applicable to common shares - -107.25M -135.12M -279.82M -303.66M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 74.31M 113.20M 172.94M 348.53M 495.94M
Intangible assets - - - 2.13M 2.63M
Other current assets 2.61M 2.52M 5.41M 50.51M 39.10M
Total liab 50.21M 44.69M 55.60M 126.17M 96.27M
Total stockholder equity 24.10M 68.50M 117.35M 222.36M 399.67M
Deferred long term liab - - - 0.03M -
Other current liab 38.23M 26.39M 18.74M 13.16M 38.35M
Common stock 0.07M 0.04M 0.02M 0.25M 0.22M
Capital stock 0.07M 0.04M 0.02M 0.25M 0.22M
Retained earnings -1815.17M -1730.22M -1622.97M -1487.85M -1209.86M
Other liab - - - 0.03M 0.11M
Good will - - 0.00M 10.51M 10.51M
Other assets - -1.70M 0.00M 0.68M 1.43M
Cash 44.27M 65.81M 14.31M 46.33M 71.14M
Total current liabilities 43.67M 35.33M 42.57M 96.87M 65.74M
Current deferred revenue - - - - 0.02M
Net debt -34.91M -53.95M 15.90M -14.25M -38.12M
Short term debt 2.82M 2.50M 19.18M 2.80M 2.60M
Short long term debt - - 16.77M - -
Short long term debt total 9.37M 11.87M 30.21M 32.07M 33.02M
Other stockholder equity 1839.83M 1799.36M 1740.95M 1710.66M 1609.59M
Property plant equipment - - - 7.73M 17.45M
Total current assets 61.12M 97.83M 153.11M 315.24M 448.44M
Long term investments 2.10M 1.61M 2.78M 2.01M 3.91M
Net tangible assets - - - 209.72M 386.53M
Short term investments 14.24M 28.30M 130.98M 206.67M 330.17M
Net receivables 0.00M 1.20M 2.41M 11.74M 8.03M
Long term debt - - - 16.61M 14.96M
Accounts payable 2.62M 6.44M 4.65M 80.91M 24.76M
Accumulated other comprehensive income -0.64M -0.68M -0.66M -0.70M -0.28M
Common stock total equity - - - 0.25M 0.22M
Retained earnings total equity - - - -1487.85M -1209.86M
Non currrent assets other 2.01M 1.98M 0.61M 0.68M 1.43M
Non current assets total 13.19M 15.37M 19.83M 33.29M 47.50M
Capital lease obligations 9.37M 11.87M 13.44M 15.46M 18.06M
Long term debt total - - - 16.61M -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 14.33M 104.07M 121.41M 112.56M -174.11M
Change to liabilities - - - 32.59M 26.10M
Total cashflows from investing activities 14.04M 104.07M 87.36M 109.59M -175.34M
Net borrowings 0.00M -16.41M 0.00M - -
Total cash from financing activities 53.05M 51.48M 5.00M 81.84M 211.50M
Change to operating activities - - - -6.95M 16.19M
Net income -84.95M -107.25M -135.12M -279.82M -303.66M
Change in cash -21.54M 51.50M -32.02M -24.81M -179.58M
Begin period cash flow 65.81M 14.31M 46.33M 71.14M 250.73M
End period cash flow 44.27M 65.81M 14.31M 46.33M 71.14M
Total cash from operating activities -88.63M -104.08M -124.37M -216.22M -215.71M
Issuance of capital stock 34.91M 36.03M 10.29M 82.96M 209.44M
Depreciation 2.99M 3.13M 3.50M 5.50M 4.73M
Other cashflows from investing activities -1176.33M 0.06M 6.22M -2.00M -
Change to inventory - - - - 15.55M
Change to account receivables - 1.21M 9.33M -3.71M 11.03M
Sale purchase of stock - - - 82.96M 209.44M
Other cashflows from financing activities -0.11M -0.42M -0.47M -1.11M 2.06M
Change to netincome - - - 30.01M 27.46M
Capital expenditures 0.29M 0.49M 0.32M 0.97M 1.23M
Change receivables - - - -3.71M 11.03M
Cash flows other operating - - - 1.87M 18.17M
Cash and cash equivalents changes - - - -24.79M -179.55M
Change in working capital -9.22M -2.66M -10.26M 19.83M 50.35M
Stock based compensation 3.76M 6.60M 11.07M 22.56M 26.34M
Other non cash items -1.21M -3.88M 6.47M 15.72M 0.86M
Free cash flow -88.92M -104.56M -124.69M -217.18M -216.94M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
INO
Inovio Pharmaceuticals Inc		 0.20
16.05%		 1.41 - 16.58 961.51 27.91 921.12 -1.09
NVO
Novo Nordisk A/S		 0.47
1.18%		 40.78 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 4.59
0.85%		 547.09 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc		 1.45
0.16%		 904.35 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. The company's lead product candidate is INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade squamous intraepithelial lesions; INO-3112 for the treatment of HPV-related Oropharyngeal squamous cell carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 2/3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. The company's partners and collaborators ApolloBio Corporation, AstraZeneca, Coherus Biosciences, Defense Advanced Research Projects Agency, HIV Vaccines Trial Network, Kaneka Eurogentec, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter BioLogics, the University of Pennsylvania, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.

660 West Germantown Pike, Plymouth Meeting, PA, United States, 19462

267 440 4200

https://www.inovio.com

112

Name Title Year Born
Dr. Jacqueline E. Shea Ph.D. CEO, Pres & Director 1966
Mr. Peter D. Kies Chief Financial Officer 1963
Dr. Laurent M. Humeau Ph.D. Chief Scientific Officer 1967
Ben Matone Director of Investor Relations NA
Mr. Robert L. Crotty J.D. Gen. Counsel 1974
Ms. Asli Gevgilili Chief HR Officer NA
Mr. E. J. Brandreth MBA Sr. VP of Quality Assurance NA
Dr. Jeffrey Skolnik Sr. VP of Clinical Devel. NA
Mr. Robert J. Juba Jr. Sr. VP of Biological Manufacturing & Clinical Supply Management NA
Mr. Daniel Jordan Sr. VP of Device Manufacturing Operations NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.96
+38.15%
MOON
CAD 4.83
+9.64%
PDN
CAD 8.13
+7.68%
BDT
CAD 72.82
+6.65%
HG
CAD 4.28
+6.20%
CSU
CAD 3300.00
-6.42%
CURA
CAD 12.68
-4.16%
DIV
CAD 3.93
-3.44%
SOIL
CAD 7.18
-3.10%
OBE
CAD 13.31
-2.92%

Equity Sectors*

  • Basic Materials

    +3.19%

  • Communication Services

    -0.04%

  • Consumer Cyclical

    +0.27%

  • Consumer Defensive

    -0.21%

  • Energy

    +1.16%

  • Financial Services

    +0.81%

  • Healthcare

    +0.03%

  • Industrials

    +1.64%

  • Real Estate

    +0.06%

  • Technology

    +0.38%

  • Utilities

    +0.68%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…